A short history of anti-rheumatic therapy - VII. Biological agents

Submitted: 9 November 2011
Accepted: 9 November 2011
Published: 9 November 2011
Abstract Views: 1217
PDF: 1115
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

The introduction of biological agents has been a major turning-point in the treatment of rheumatic diseases, particularly in rheumatoid arthritis. This review describes the principle milestones that have led, through the knowledge of the structure and functions of nucleic acids, to the development of production techniques of the three major families of biological agents: proteins, monoclonal antibodies and fusion proteins. A brief history has also been traced of the cytokines most involved in the pathogenesis of inflammatory rheumatic diseases (IL-1 and TNF) and the steps which have led to the use of the main biological drugs in rheumatology: anakinra, infliximab, adalimumab, etanercept and rituximab.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Citations

How to Cite

Pasero, G., Marson, P., & Gatto, B. (2011). A short history of anti-rheumatic therapy - VII. Biological agents. Reumatismo, 63(3), 185–194. https://doi.org/10.4081/reumatismo.2011.185